Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

January 2019

TriVisc and Jivi Now Covered with Prior Authorization


As you are aware, prior authorizations are required for select medical drugs for Harvard Pilgrim’s commercial members through CVS Health–NovoLogix. Several coagulation antihemophilic Factor VIII medications for hemophilia A and hyaluronate preparations for osteoarthritis of the knee are currently managed via this prior authorization management program. Harvard Pilgrim is now covering two additional drugs that fall under those categories — Jivi (antihemophilic factor (recombinant), pegylated-aucl for injection) and TriVisc (sodium hyaluronate) — with prior authorization through CVS Health—NovoLogix.

The following CPT codes will be added to the list of codes associated with the commercial medical drug prior authorization program:

  • J7199 – Hemophilia clotting factor, not otherwise classified
  • J3490 – Unclassified drugs
  • J3590 – Unclassified biologics

For complete information, please refer to the Factor VIII Concentrates Medical Review Criteria and TriVisc Medical Review Criteria and the associated prior authorization request forms, which you can find on the Medical Drug Prior Authorization page in the Provider section of Harvard Pilgrim’s website.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

HPHConnect for Providers Getting a New Look in 2019

2019 Quality Grant Applications Due by Feb. 15

HEDIS 2019 Coming Soon: Your Cooperation is Crucial

HPI to Administer BMC HealthNet Plan

Behavioral Health: Services for Improved Access

CLINICIAN CORNER

New Opioid Safety Edits for 2019 Medicare Advantage Plans

Medical Policy Update: Tumor Treating Fields

Reminder: Formulas and Enteral Nutrition Require Prior Authorization

Updates to Proton Beam Therapy Medical Policy

Lumoxiti Now Covered with Prior Authorization

TriVisc and Jivi Now Covered with Prior Authorization

Pharmacy and Therapeutics Committee Meeting Update

OFFICE ASSISTANT

Coding Program Launching in January for Medicare Advantage

PUBLICATION INFORMATION

Robert Farias,
Senior Vice President, Corporate Network Strategy

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator